Problems in the metabolism of low-density lipoprotein (LDL) — also known as “bad cholesterol” — and its receptor contribute to changes in lung cells that ultimately lead to pulmonary fibrosis (PF), an analysis of fibrotic lung tissue and cell and animal models suggests. Notably, a combination of two approved…
It’s normal for people to come and go in our life. Our circle of friends changes when we change schools, start a new job, get married or divorced, and have children. Being diagnosed with idiopathic pulmonary fibrosis (IPF) had the same effect on my group of friends. As my IPF…
Eperisone — an oral muscle relaxant used to treat muscle spasms and rigidity — significantly eased lung scarring and improved lung function in a mouse model of idiopathic pulmonary fibrosis (IPF), a study shows. Comparisons between eperisone and the approved IPF therapies Ofev (nintedanib) and Esbriet (pirfenidone) in…
OncoArendi Therapeutics and the University of Michigan (U-M) have signed an option-to-license agreement, allowing the Poland-based biotech company to develop new therapies to treat fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). “We are thrilled to be partnering with the University of Michigan, one of the world’s leading research…
Have you ever gotten into the car, started driving, and then snapped out of a trance at your destination with no memory of the trip? Let’s call it driving on autopilot. Relying on your reflexes to operate a vehicle is certainly one way to get from point A…
RXC007, an experimental oral treatment of idiopathic pulmonary fibrosis (IPF) being developed by Redx Pharma, continues to be safe and well-tolerated in a Phase 1 study in healthy volunteers, the company reported. “Clinical data from our Phase 1 study suggests that RXC007 is safe and well-tolerated at the drug doses…
No one will ever convince me that COVID-19 is just a cold. Unfortunately, I’ve heard this sentiment echoed by healthy friends since the start of the pandemic as a means of downplaying public health measures meant to curb the spread of the virus. But having had COVID-19 twice now, I’ll…
Bridge Biotherapeutics has entered into an exclusive option-to-license agreement with Cellion BioMed to develop BBT-301, an experimental ion modulator therapy, as a potential treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. “We are highly excited to in-license BBT-301, a novel drug candidate for the treatment of fibrotic…
Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…
What a rough three weeks my family has been having. I’ve had to put a hold on writing my column because of events outside of my control. Once again, I am angry with this rare illness of mine. It not only puts a hold on my life, but…
Get regular updates to your inbox.
